Anzeige
Mehr »
Login
Samstag, 18.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
GOLD-MINEN vor Jahrhundert-Hausse?! Diese Aktie sofort kaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
350 Leser
Artikel bewerten:
(1)

Suvoda LLC: Suvoda Announces Participation at CTS Europe Conference in Madrid, March 22-23

Global Clinical Trial Technology Leader to Participate in Two Presentations for the Conference on Clinical Trial Supply Chain

PHILADELPHIA, March 17, 2022 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in highly complex studies, such as oncology, central nervous system (CNS) and rare disease, today announced that its Director of Services Delivery, Europe will be a key presenter and panelist in two sessions at the upcoming Clinical Trial Supply (CTS) Europe conference in Madrid, Spain taking place from March 22-23. More than 300 attendees and over 50 exhibitors are expected at this year's conference. CTS Europe will bring together pharmaceutical and biotech companies to discuss clinical trial supply chain operations, processes, tools, and techniques.

In its first industry event since announcing a corporate rebranding earlier this month, Suvoda will be sharing clinical trial supply strategy insights and best practices in two key presentations on March 22, including:

How to Optimize your Trial Supply Chain with a Flexible IRT
Tuesday, March 22, 2022 | 10:00 AM CET
Overview: Attendees will gain insight into the value of IRT for improved supply chain efficiency
Speakers:

  • Marcel Besier, Director of Services Delivery, Europe, Suvoda
  • Daniela Duffett, Solutions Consultant, Suvoda

Panel Discussion - Navigating the Journey to Decentralized Trials: Establishing a Successful Patient-Centric Clinical Trial Supply Chain Resulting in Enhanced Patient Retention
Tuesday, March 22, 2022 | 4:30 PM CET
Moderator: Jennifer Smith-Parker, Senior Editor, GD Healthcare
Speakers:

  • Marcel Besier, Director of Services Delivery, Europe, Suvoda
  • Marcus Wajngarten, Senior Director, Home Supply, AstraZeneca
  • Bernard Jaucot, Senior Director PSO, Global Clinical Supplies, PPD, part of Thermo Fisher Scientific

Building on Suvoda's momentum in 2021, the Company recently refreshed its brand and expanded beyond its flagship IRT product with the release of its eConsent and eCOA solutions, now in the early adopter phase, marking a critical step in the company's path to streamline complex clinical trials.

Suvoda will be highlighting these developments and how companies can Trial wisely at the CTS Europe conference this month. For more details, you can register for CTS Europe here and experience the new Suvoda at www.suvoda.com.

About Suvoda
Suvoda is a global clinical trial technology company that specializes in highly complex, life-sustaining studies in therapeutic areas like oncology, central nervous system, and rare disease. Founded in 2013 by experts in eClinical technologies, Suvoda empowers clinical trial professionals to manage the most urgent moments in the most urgent trials through its IRT, eConsent, and eCOA solutions delivered on a single platform. Headquartered outside Philadelphia, Suvoda also maintains offices in Portland, OR, Barcelona, Spain, Bucharest, Romania and Tokyo, Japan. The company consistently boasts a customer satisfaction index of 9 out of 10, an NPS score of 70 in its annual surveys, and has been selected by trial sponsors and CROs to support nearly 1000 trials across 65 countries. To learn more, visit suvoda.com. Follow Suvoda on Twitter and LinkedIn.

Logo - https://mma.prnewswire.com/media/1759317/Suvoda_Logo.jpg

KI-Champions: 3 Top-Werte, die Ihr Portfolio revolutionieren
Fordern Sie jetzt den brandneuen kostenfreien Sonderreport an und erfahren Sie, wie Sie von den enormen Wachstumschancen im Bereich Künstliche Intelligenz profitieren können - 100 % kostenlos.
Hier klicken
© 2022 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.